Cancer Stem Cell News Volume 2.50 | Dec 18 2013

Cancer Stem Cell News 2.50 December 18, 2013

Cancer Stem Cell News

     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Cancer Stem Cell News on Twitter

Colon Cancer Cells Escape 5FU Chemotherapy-Induced Cell Death by Entering Stemness and Quiescence Associated with the c-Yes/YAP Axis
Investigators aimed to identify the mechanisms underlying HT29 colon cancer cell chemoresistance acquired after sequential exposure to 5-fluorouracil (5FU), a classical anticancer drug for treatment of epithelial solid tumors. They examined its clinical relevance in a cohort of colon cancer patients with liver metastases after 5FU-based neoadjuvant chemotherapy and surgery. [Clin Cancer Res] Abstract
Culture Human Glioma-Derived Tumorspheres with NeuroCult™ - View Publications

PUBLICATIONS (Ranked by impact factor of the journal)
The Stem Cell Factor SOX2 Regulates the Tumorigenic Potential in Human Gastric Cancer Cells
To elucidate the role of Sox2 in gastric tumorigenesis, Sox2 transcriptional activity was blocked in AZ-521 cells. Inhibition of Sox2 reduced cell proliferation and migration, increased apoptosis and induced changes in cell cycle. [Carcinogenesis] Abstract

Sorcin Silencing Inhibits Epithelial-to-Mesenchymal Transition and Suppresses Breast Cancer Metastasis In Vivo
Researchers demonstrated that sorcin depletion in MDA-MB-231 breast cancer cells reduces the pool of CD44+/CD24 and ALDH1high cancer stem cells as well as mammosphere-forming capacity. [Breast Cancer Res Treat] Abstract

Distribution of LGR5+ Cells and Associated Implications during the Early Stage of Gastric Tumorigenesis
Lineage tracing indicates that Lgr5+ cells may not only be the cells responsible for the origin of tumors; they may also be the so-called cancer stem cells. Scientists investigated the presence of Lgr5+ cells and their biological significance in normal human gastric mucosa and gastric tumors. [PLoS One] Full Article

Isolation of Cancer Stem Like Cells from Human Adenosquamous Carcinoma of the Lung Supports a Monoclonal Origin from a Multipotential Tissue Stem Cell
Investigators isolated and characterized cancer stem-like populations from adenosquamous carcinoma through application of selective defined culture medium initially used to grow human lung stem cells. [PLoS One]
Full Article | Press Release

Genistein Decreases the Breast Cancer Stem-Like Cell Population through Hedgehog Pathway
Researchers aimed to evaluate genistein inhibition of breast cancer stem-like cells and its potential mechanism by culturing MCF-7 breast cancer cells and implanting these cells into nude mice. [Stem Cell Res Ther] Abstract | Full Article

SP Cell Fractions from HCC Cell Lines Increased with Tumor Dedifferentiation, but Lack Characteristic Features of CSCs
Putative cancer stem cell (CSC) markers, such as CD13, CD90, CD133, and EpCAM, and side population (SP) technique are generally used in an attempt to isolate CSCs. Investigators aimed to clarify the relationship between CSCs and clonal dedifferentiation in hepatocellular carcinoma (HCC). [J Gastroenterol Hepatol] Abstract

A 3D Multiscale Model of Cancer Stem Cell in Tumor Development
A novel 3D multi-scale mathematical modeling was proposed to investigate the behaviors of cancer stem cells (CSCs) in tumor progressions. The model integrates CSCs, progenitor tumor cells, and differentiated tumor cells together with a few essential microenvironment factors. [BMC Systems Biol] Full Article

Knockdown of Bmi1 Inhibits the Stemness Properties and Tumorigenicity of Human Bladder Cancer Stem Cell-Like Side Population Cells
Investigators aimed to assess the role of B-cell-specific Moloney murine leukemia virus insertion site 1 (Bmi1) in the maintenance of stemness properties and tumorigenicity of human bladder cancer stem cell-like side population cells. [Oncol Rep] Abstract

Use Aldefluor to Detect Breast Cancer Stem Cells - Click here to learn more

The Roles of FOXM1 in Pancreatic Stem Cells and Carcinogenesis
The authors describe the current knowledge about the signaling pathways related to pancreatic cancer stem cells (PCSCs) and the early stages of pancreatic ductal adenocarcinoma development, highlighting the pivotal roles of Forkhead box protein M1 (FOXM1) in PCSCs and their impacts on the development and progression of pancreatic intraepithelial neoplasia. [Mol Cancer] Full Article

Immunology of Cancer Stem Cells in Solid Tumors. A Review
This review summarizes findings on the immunological profile of cancer stem cells (CSCs)/tumor-initiating cells (TICs) as compared with neoplastic non-stem cells and discusses the possible antigens recognized by the patients’ immune system, the in vitro and the potential in vivo immunogenicity of such antigens and the ability of human CSCs/TICs to down-regulate the immune response by the release of a variety of suppressive factors. [Eur J Cancer] Abstract

Visit our reviews page to see a complete list of reviews in the cancer stem cell research field.

Enter to Win: Free ISCT 2014 Conference Registration in Paris, France!

With New Multimillion-Dollar Grants, UCLA Scientists Take Stem Cell Research to Patients
A team led by University of California, Los Angeles (UCLA)’s Dr. Dennis Slamon and Dr. Zev Wainberg was awarded nearly $7 million for a clinical trial that will test a new drug targeting cancer stem cells, and UCLA’s Dr. Donald Kohn received almost $14 million for a clinical trial that will focus on stem-cell gene therapy for sickle cell disease. [University of California, Los Angeles] Press Release

Stem Cell Therapeutics Completes $33 Million Private Placement
Stem Cell Therapeutics Corp. announced that it has raised gross proceeds of $33 million through a private placement of units. The financing proceeds will be used to advance the Company’s CD47 cancer stem cell program through IND-enabling studies, manufacturing and Phase I clinical trials. [Stem Cell Therapeutics, Inc.] Press Release

Cellular Biomedicine Group Announces Completion of Patient Treatment for Phase I Clinical Trial for Liver Cancer
Cellular Biomedicine Group, Inc. announced that it has treated the final patient of its Phase I clinical trial which evaluates the safety and preliminary efficacy of tumor stem cell specific dendritic cell therapy for hepatocellular carcinoma, the most common type of liver cancer. [Cellular Biomedicine Group, Corp.] Press Release

New wallchart from our sponsor:
Mesenchymal Stem Cells (a Nature Reviews Molecular Cell Biology collaboration). Request your free copy.

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

NEW 33rd Annual Convention of Indian Association for Cancer Research
February 12-15, 2014
Kollam, India

Visit our events page to see a complete list of events in the cancer stem cell community.

NEW Research Associate – Stem Cell & Leukemia Epigenetic (King’s College London)

Postdoctoral Position – Stem Cells and Bioengineering (Queensland University of Technology/Translational Research Institute)

Clinical MD – Clinical Development Program for Oncology and Autoimmune Diseases (Immunomedics, Inc.)

Chief Medical Officer – Novel Therapeutics in Oncology and Autoimmune Disease (Immunomedics, Inc.)

Postdoctoral Position – Apoptosis, Cancer Biology (Washington State University)

Postdoctoral Position – Skin Stem Cell and Cancer Biology (Karolinska Institutet)

Postdoctoral Position – Nervous System Development and Tumor Biology (Karolinska Institutet)

Postdoctoral Fellow – Breast Cancer Stem Cell Biology (University of Cincinnati)

Research Fellowship – Cancer Biology (Harvard Medical School)

Assistant Professor – Fundamental Mechanisms in Cancer Biology (Cornell University)

Scientist – Particle Chemistry (STEMCELL Technologies Inc.)

Research Technologist – Human Pluripotent Stem Cell Products (STEMCELL Technologies Inc.)

Research Associate/Scientist – Antibodies Group (STEMCELL Technologies Inc.)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.


Have we missed an important article or publication in Cancer Stem Cell News? Click here to submit!

Comments or Suggestions? Email Comments or suggestions? Submit your feedback here

Learn more about Cancer Stem Cell News: Archives | Events | Contact Us